EdgarLookup

Lifeward Ltd. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Lifeward Ltd. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-90.4%
Profit Margin
Net income ÷ revenue
-87%
Return on Assets
Net income ÷ assets
1.72x
Debt-to-Equity
Total liabilities ÷ equity
-14.1%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $22.03M Mar 18, 2026
FY2025 Dec 31, 2024 $25.66M Mar 18, 2026
FY2025 Dec 31, 2023 $13.85M Mar 18, 2026
FY2024 Dec 31, 2022 $5.51M Mar 7, 2025
FY2023 Dec 31, 2021 $5.97M Feb 27, 2024
FY2022 Dec 31, 2020 $4.39M Feb 23, 2023
FY2021 Dec 31, 2019 $4.87M Feb 24, 2022
FY2020 Dec 31, 2018 $6.55M Feb 18, 2021
FY2019 Dec 31, 2017 $7.75M Feb 20, 2020
FY2018 Dec 31, 2016 $5.87M Feb 8, 2019

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.40M Mar 18, 2026
FY2024 Dec 31, 2024 $1.70M Mar 7, 2025
FY2023 Dec 31, 2023 $435.0K Feb 27, 2024
FY2022 Dec 31, 2022 $352.0K Feb 23, 2023
FY2021 Dec 31, 2021 $432.0K Feb 24, 2022
FY2020 Dec 31, 2020 $330.0K Feb 18, 2021
FY2018 Dec 31, 2017 $135.0K Feb 8, 2019

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $8.43M Mar 18, 2026
FY2025 Dec 31, 2024 $8.22M Mar 18, 2026
FY2025 Dec 31, 2023 $4.45M Mar 18, 2026
FY2024 Dec 31, 2022 $1.91M Mar 7, 2025
FY2023 Dec 31, 2021 $2.90M Feb 27, 2024
FY2022 Dec 31, 2020 $2.19M Feb 23, 2023
FY2021 Dec 31, 2019 $2.73M Feb 24, 2022
FY2020 Dec 31, 2018 $2.83M Feb 18, 2021
FY2019 Dec 31, 2017 $3.10M Feb 20, 2020
FY2018 Dec 31, 2016 $736.0K Feb 8, 2019

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($19.91M) Mar 18, 2026
FY2025 Dec 31, 2024 ($28.94M) Mar 18, 2026
FY2025 Dec 31, 2023 ($22.13M) Mar 18, 2026
FY2024 Dec 31, 2022 ($19.57M) Mar 7, 2025
FY2023 Dec 31, 2021 ($12.74M) Feb 27, 2024
FY2022 Dec 31, 2020 ($12.98M) Feb 23, 2023
FY2021 Dec 31, 2019 ($15.55M) Feb 24, 2022
FY2020 Dec 31, 2018 ($21.68M) Feb 18, 2021
FY2019 Dec 31, 2017 ($24.72M) Feb 20, 2020
FY2018 Dec 31, 2016 ($32.50M) Feb 8, 2019

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($19.67M) Mar 18, 2026
FY2025 Dec 31, 2024 ($29.35M) Mar 18, 2026
FY2025 Dec 31, 2023 ($23.61M) Mar 18, 2026
FY2024 Dec 31, 2022 ($19.10M) Mar 7, 2025
FY2023 Dec 31, 2021 ($12.66M) Feb 27, 2024
FY2022 Dec 31, 2020 ($12.00M) Feb 23, 2023
FY2021 Dec 31, 2019 ($14.05M) Feb 24, 2022
FY2020 Dec 31, 2018 ($19.21M) Feb 18, 2021
FY2019 Dec 31, 2017 ($21.99M) Feb 20, 2020
FY2018 Dec 31, 2016 ($30.44M) Feb 8, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $3.25M Mar 18, 2026
FY2025 Dec 31, 2024 $4.63M Mar 18, 2026
FY2025 Dec 31, 2023 $4.15M Mar 18, 2026
FY2024 Dec 31, 2022 $4.03M Mar 7, 2025
FY2023 Dec 31, 2021 $2.94M Feb 27, 2024
FY2022 Dec 31, 2020 $3.46M Feb 23, 2023
FY2021 Dec 31, 2019 $5.35M Feb 24, 2022
FY2020 Dec 31, 2018 $7.35M Feb 18, 2021
FY2019 Dec 31, 2017 $6.04M Feb 20, 2020
FY2018 Dec 31, 2016 $9.03M Feb 8, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($16.83M) Mar 18, 2026
FY2025 Dec 31, 2024 ($21.72M) Mar 18, 2026
FY2025 Dec 31, 2023 ($20.67M) Mar 18, 2026
FY2024 Dec 31, 2022 ($17.89M) Mar 7, 2025
FY2023 Dec 31, 2021 ($11.47M) Feb 27, 2024
FY2022 Dec 31, 2020 ($12.59M) Feb 23, 2023
FY2021 Dec 31, 2019 ($14.82M) Feb 24, 2022
FY2020 Dec 31, 2018 ($14.77M) Feb 18, 2021
FY2019 Dec 31, 2017 ($22.46M) Feb 20, 2020
FY2018 Dec 31, 2016 ($26.75M) Feb 8, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $16.0K Mar 18, 2026
FY2025 Dec 31, 2024 $0 Mar 18, 2026
FY2025 Dec 31, 2023 $81.0K Mar 18, 2026
FY2024 Dec 31, 2022 $25.0K Mar 7, 2025
FY2023 Dec 31, 2021 $47.0K Feb 27, 2024
FY2022 Dec 31, 2020 $73.0K Feb 23, 2023
FY2021 Dec 31, 2019 $22.0K Feb 24, 2022
FY2020 Dec 31, 2018 $13.0K Feb 18, 2021
FY2019 Dec 31, 2017 $21.0K Feb 20, 2020
FY2018 Dec 31, 2016 $452.0K Feb 8, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $22.90M Mar 18, 2026
FY2025 Dec 31, 2024 $30.49M Mar 18, 2026
FY2024 Dec 31, 2023 $63.19M Mar 7, 2025
FY2023 Dec 31, 2022 $74.24M Feb 27, 2024
FY2022 Dec 31, 2021 $94.75M Feb 23, 2023
FY2021 Dec 31, 2020 $28.07M Feb 24, 2022
FY2020 Dec 31, 2019 $24.37M Feb 18, 2021
FY2019 Dec 31, 2018 $14.96M Feb 20, 2020
FY2018 Dec 31, 2017 $22.86M Feb 8, 2019
FY2017 Dec 31, 2016 $31.76M Mar 8, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $14.49M Mar 18, 2026
FY2025 Dec 31, 2024 $11.64M Mar 18, 2026
FY2024 Dec 31, 2023 $16.68M Mar 7, 2025
FY2023 Dec 31, 2022 $6.07M Feb 27, 2024
FY2022 Dec 31, 2021 $5.37M Feb 23, 2023
FY2021 Dec 31, 2020 $6.29M Feb 24, 2022
FY2020 Dec 31, 2019 $13.59M Feb 18, 2021
FY2019 Dec 31, 2018 $13.02M Feb 20, 2020
FY2018 Dec 31, 2017 $19.16M Feb 8, 2019
FY2017 Dec 31, 2016 $23.50M Mar 8, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $8.41M Mar 18, 2026
FY2025 Dec 31, 2024 $18.85M Mar 18, 2026
FY2025 Dec 31, 2023 $46.51M Mar 18, 2026
FY2025 Dec 31, 2022 $68.17M Mar 18, 2026
FY2024 Dec 31, 2021 $89.38M Mar 7, 2025
FY2023 Dec 31, 2020 $21.77M Feb 27, 2024
FY2022 Dec 31, 2019 $10.78M Feb 23, 2023
FY2021 Dec 31, 2018 $1.95M Feb 24, 2022
FY2020 Dec 31, 2017 $3.71M Feb 18, 2021
FY2019 Dec 31, 2016 $8.26M Feb 20, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $4.76M Mar 18, 2026
FY2025 Dec 31, 2024 $7.54M Mar 18, 2026
FY2024 Dec 31, 2023 $7.54M Mar 7, 2025
FY2023 Dec 31, 2022 $0 Feb 27, 2024

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($284.74M) Mar 18, 2026
FY2025 Dec 31, 2024 ($264.83M) Mar 18, 2026
FY2024 Dec 31, 2023 ($235.88M) Mar 7, 2025
FY2023 Dec 31, 2022 ($213.75M) Feb 27, 2024
FY2022 Dec 31, 2021 ($194.18M) Feb 23, 2023
FY2021 Dec 31, 2020 ($181.45M) Feb 24, 2022
FY2020 Dec 31, 2019 ($168.47M) Feb 18, 2021
FY2019 Dec 31, 2018 ($152.92M) Feb 20, 2020
FY2018 Dec 31, 2017 ($131.22M) Feb 8, 2019
FY2017 Dec 31, 2016 ($106.49M) Mar 8, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.17M Mar 18, 2026
FY2025 Dec 31, 2024 $6.75M Mar 18, 2026
FY2024 Dec 31, 2023 $28.08M Mar 7, 2025
FY2023 Dec 31, 2022 $67.90M Feb 27, 2024
FY2022 Dec 31, 2021 $88.34M Feb 23, 2023
FY2021 Dec 31, 2020 $20.35M Feb 24, 2022
FY2020 Dec 31, 2019 $16.25M Feb 18, 2021
FY2019 Dec 31, 2018 $9.55M Feb 20, 2020
FY2018 Dec 31, 2017 $14.57M Feb 8, 2019
FY2017 Dec 31, 2016 $23.68M Mar 8, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (17) Mar 18, 2026
FY2025 Dec 31, 2024 (39) Mar 18, 2026
FY2023 Dec 31, 2023 0 Feb 27, 2024
FY2025 Dec 31, 2023 (31) Mar 18, 2026
FY2024 Dec 31, 2022 (2) Mar 7, 2025
FY2023 Dec 31, 2022 0 Feb 27, 2024
FY2023 Dec 31, 2021 0 Feb 27, 2024
FY2023 Dec 31, 2021 0 Feb 27, 2024
FY2022 Dec 31, 2020 0 Feb 23, 2023

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (17) Mar 18, 2026
FY2025 Dec 31, 2024 (39) Mar 18, 2026
FY2023 Dec 31, 2023 0 Feb 27, 2024
FY2025 Dec 31, 2023 (31) Mar 18, 2026
FY2023 Dec 31, 2022 0 Feb 27, 2024
FY2024 Dec 31, 2022 (2) Mar 7, 2025
FY2023 Dec 31, 2021 0 Feb 27, 2024
FY2023 Dec 31, 2021 0 Feb 27, 2024
FY2022 Dec 31, 2020 0 Feb 23, 2023

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 1.52M Mar 18, 2026
FY2025 Dec 31, 2024 733,966 Mar 18, 2026
FY2024 Dec 31, 2023 8.59M Mar 7, 2025
FY2023 Dec 31, 2022 60.09M Feb 27, 2024
FY2022 Dec 31, 2021 62.48M Feb 23, 2023
FY2021 Dec 31, 2020 25.33M Feb 24, 2022
FY2020 Dec 31, 2019 7.32M Feb 18, 2021
FY2019 Dec 31, 2018 2.81M Feb 20, 2020
FY2018 Dec 31, 2017 30.00M Feb 8, 2019
FY2017 Dec 31, 2016 16.34M Mar 8, 2018